By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

ImmusanT, Inc. 

One Broadway
14th Floor
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-401-2154 Fax: n/a


SEARCH JOBS


Industry
Biotechnology

Segment
Biotechnology





Company News
ImmusanT, Inc. Announces Publication Of Positive Data From Phase I Trials Of Nexvax2 In Celiac Disease Patients 5/12/2017 6:19:24 AM
ImmusanT, Inc. Reports Data On Novel Celiac Disease Diagnostic Approach 5/8/2017 10:20:59 AM
ImmusanT, Inc. Announces Completion Of Phase Ib Clinical Trial Of Nexvax2 For The Treatment Of Celiac Disease 2/22/2017 6:37:22 AM
ImmusanT, Inc. Reports Nexvax2 Phase 1 Data In Patients With Celiac Disease 5/25/2016 9:29:04 AM
ImmusanT, Inc. Release: Journal Gastroenterology Publishes Research Indicating Nearly Identical Response To Gluten In Most Children And Adults With Celiac Disease 9/2/2015 10:41:58 AM
ImmusanT, Inc. Release: Journal Gastroenterology Publishes Research Indicating Nearly Identical Response To Gluten In Most Children And Adults With Celiac Disease 9/2/2015 9:51:07 AM
ImmusanT, Inc. Banks $12 Million Series B 12/22/2014 7:08:41 AM
ImmusanT, Inc.’s Immunotherapy For Celiac Disease, Nexvax2, Selected As One Of Informa’s Top 10 Autoimmune/Anti-Inflammatory Projects To Watch 11/19/2014 5:04:11 PM
ImmusanT, Inc. Release: New Test In Celiac Disease Provides Powerful Tool For Diagnosis And Immune Monitoring 1/6/2014 9:52:33 AM
ImmusanT, Inc. Names Ferdinand E. Massari as Chief Medical Officer 9/9/2013 6:48:00 AM
12
//-->